ADMA Biologics
ADMA
19 hedge funds and large institutions have $68.7M invested in ADMA Biologics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 10 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
25% more capital invested
Capital invested by funds: $55.1M → $68.7M (+$13.6M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
30% less funds holding
Funds holding: 27 → 19 (-8)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$4.66M |
| 2 |
IHM
Iguana Healthcare Management
New York
|
+$159K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$147K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$98.9K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$53.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$855K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$595K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$446K |
| 4 |
TI
Telemetry Investments
New York
|
-$254K |
| 5 |
PVI
Pura Vida Investments
New York
|
-$217K |
ADMA Hedge Fund Activity: Q3 2016 in Review
19 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2016, worth a combined $68.7M — up 25% from $55.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ADMA and 2 opened new positions — a net loss of 8 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $4.66M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $855K sold.
- 19 institutional investors held ADMA Biologics (ADMA) as of Q3 2016, down from 27 in Q2 2016.
- Funds reported $68.7M of ADMA Biologics stock for Q3 2016, up 25% quarter-over-quarter.
- 2 funds opened new ADMA Biologics positions in Q3 2016 and 10 closed out, a net change of -8 holders.
- The largest ADMA Biologics buyer in Q3 2016 was Perceptive Advisors, an estimated $4.66M added.
- The largest ADMA Biologics seller in Q3 2016 was J. Goldman & Co, an estimated $855K sold.
Based on aggregated 13F filings for Q3 2016.